☆ 4.6 Article

Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group

FRONTIERS IN MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Dermatology

Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice

A. Ruggiero et al.

Summary: The study indicated that three anti-IL-23 therapies are promising, safe, and effective options for elderly patients with psoriasis, with no significant differences found between them. However, more data is required to confirm these results and understand their role in the management of this patient group. Limitations of the study included small sample size and varied follow-up durations.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

Add to Collection

Article Dermatology

A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results

Nina Magnolo et al.

Summary: The study evaluated the efficacy and safety of two secukinumab dosage regimens in pediatric patients with moderate to severe plaque psoriasis, showing both doses were superior to historical placebo and well tolerated by the patients.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Add to Collection

Letter Dermatology

Extended dosing intervals of ixekizumab for psoriasis: A single-center, uncontrolled, prospective study

Li-Ran Ye et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study

Matteo Megna et al.

Summary: This real-life study compared the efficacy and safety of anti-IL23 drugs for psoriasis management, and found that guselkumab, tildrakizumab, and risankizumab showed comparable efficacy and safety profiles, with guselkumab and risankizumab appearing slightly more effective for palmoplantar lesions in the short term.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

Add to Collection

Article Dermatology

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial

C. Bodemer et al.

Summary: In a study involving pediatric patients with severe chronic plaque psoriasis, both doses of Secukinumab (LD and HD) demonstrated high and sustained efficacy over one year, with a favorable safety profile.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review

C. A. J. Michielsens et al.

Summary: Biologic tapering appears to be effective and safe in psoriasis patients with stable low disease activity or clinical remission. More research is needed to address the current gaps in knowledge, particularly in terms of tapering criteria and strategies, long-term safety, predictors for successful tapering, cost-effectiveness, and evaluation of newer generation biologics.

DRUGS (2021)

Add to Collection

Review Pediatrics

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Hannah A. Blair

Summary: Subcutaneous secukinumab is an effective treatment option for children and adolescents with moderate to severe plaque psoriasis, providing fast and durable skin clearance, continuous improvement in health-related quality of life, and long-term maintained benefits.

PEDIATRIC DRUGS (2021)

Add to Collection

Letter Dermatology

A case of pediatric psoriasis successfully and rapidly treated with ixekizumab

Matteo Megna et al.

DERMATOLOGIC THERAPY (2021)

Add to Collection

Article Dermatology

Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE)

R. B. Warren et al.

BRITISH JOURNAL OF DERMATOLOGY (2020)

Add to Collection

Article Dermatology

A case of erythrodermic psoriasis successfully treated with guselkumab

Matteo Megna et al.

DERMATOLOGIC THERAPY (2020)

Add to Collection

Article Dermatology

Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Alan Menter et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

Article Dermatology

Efficacy and safety of ixekizumab in a phaseIII, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)

A. S. Paller et al.

BRITISH JOURNAL OF DERMATOLOGY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation

A. Zangrilli et al.

EXPERT OPINION ON DRUG SAFETY (2020)

Add to Collection

Review Immunology

Biologics switch in psoriasis

Ting-Shun Wang et al.

IMMUNOTHERAPY (2019)

Add to Collection

Article Dermatology

Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation

Vito D. Lernia et al.

DERMATOLOGIC THERAPY (2019)

Add to Collection

Review Pharmacology & Pharmacy

Biologics in pediatric psoriasis - efficacy and safety

Sunil Dogra et al.

EXPERT OPINION ON DRUG SAFETY (2018)

Add to Collection

Article Pediatrics

Treatment of severe psoriasis in children: recommendations of an Italian expert group

Anna Belloni Fortina et al.

EUROPEAN JOURNAL OF PEDIATRICS (2017)

Add to Collection

Letter Dermatology

Switching biologics in severe pediatric psoriasis: a retrospective analysis

Rita Ramos Pinheiro et al.

INTERNATIONAL JOURNAL OF DERMATOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial

Kim Papp et al.

LANCET (2017)

Add to Collection

© Peeref 2019-2024. All rights reserved.